CRYPTO 5%

Research-grade peptides. Shipped same day in Bangkok.

04 / Retatrutide

Retatrutide

Available as REVIA

Molecular profile
Sequence 39-amino-acid backbone, synthetically modified
Formula C221H342N46O68
Class Triple hormone receptor agonist

Retatrutide is an engineered single-peptide chain studied as a triple hormone receptor agonist, examined in relation to three endocrine pathways simultaneously.

GLP-1 receptor

Research examined interaction with insulinotropic mechanisms, gastric motility, and appetite feedback markers.

GIP receptor

Studies examined GIP pathway engagement alongside GLP-1 in relation to glucose-dependent insulin secretion and adipose tissue dynamics.

Glucagon receptor

Research examined glucagon receptor engagement in relation to resting metabolic energy expenditure and hepatic lipid oxidation.

Retatrutide
GLP-1 engagement
GIP engagement
Glucagon engagement
Metabolic homeostasis examined

Peer-reviewed references

  • Jastreboff AM, et al. Triple-hormone-receptor agonist retatrutide for obesity, a phase 2 trial. New England Journal of Medicine. 2023;389(6):514-526. doi.org/10.1056/NEJMoa2301972
  • Rosenstock J, Frias J, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet. 2023;402(10401):529-544. doi.org/10.1016/S0140-6736(23)01053-X

Library

Research and Whitepapers

Retatrutide: The Triple-Receptor Trials

Retatrutide adds a third receptor to the incretin approach, activating GIP, GLP-1, and glucagon receptors at once. Two phase 2 trials in humans were published in 2023, in the New England Journal of Medicine and the Lancet.

Retatrutide: Two Human Phase 2 Trials, NEJM and the Lancet

Retatrutide is the first triple GIP, GLP-1, and glucagon receptor agonist to reach late-stage human trials. Two phase 2 trials in humans were published in 2023, one in the New England Journal of Medicine and one in the Lancet.

For research purposes only. Not for human or veterinary consumption. Not for use in diagnostic, therapeutic, or clinical procedures.